A step-by-step guide to Pancreatic Cancer Procedure steps, including imaging, endoscopic ultrasound, and biopsy methods for accurate diagnosis and staging.
Send us all your questions or requests, and our expert team will assist you.
Diagnosis and Staging for pancreatic cancer is a critical step that determines the therapeutic pathway and overall prognosis. Each year, pancreatic cancer ranks among the most lethal malignancies, with a five‑year survival rate below 10 %. Early and accurate assessment can dramatically improve outcomes, especially when performed at a center experienced in managing complex oncologic cases.
This page is designed for international patients and their families who are seeking clear, detailed information about how pancreatic cancer is identified and classified. We will walk you through the diagnostic tools, staging systems, multidisciplinary workflow, emerging technologies, and practical tips for preparing for your journey at Liv Hospital.
Understanding the full diagnostic and staging process empowers patients to make informed decisions, coordinate care across borders, and feel confident that every step is guided by evidence‑based medicine and compassionate support.
Imaging forms the backbone of pancreatic cancer diagnosis. Modern modalities provide high‑resolution views of the pancreas and surrounding structures, allowing clinicians to detect lesions as small as a few millimeters.
The table below summarizes the typical sensitivity and specificity of each imaging method for detecting pancreatic adenocarcinoma.
Laboratory investigations complement imaging by indicating tumor activity and guiding further procedures. The most widely used biomarker is CA 19‑9, which is elevated in approximately 70 % of patients with advanced disease. However, CA 19‑9 lacks specificity and can be raised in benign conditions such as cholangitis.
Additional tests include:
Definitive diagnosis requires histologic confirmation. Techniques vary based on lesion location and patient fitness:
At Liv Hospital, all tissue samples are processed in a JCI‑accredited pathology laboratory, ensuring rapid turnaround and comprehensive molecular analysis.
The Tumor‑Node‑Metastasis (TNM) system, maintained by the American Joint Committee on Cancer (AJCC), remains the gold standard for pancreatic cancer staging. It evaluates three components:
Each component is assigned a numeric value (0‑4), which together define the overall stage (I‑IV). Accurate TNM assessment guides surgical eligibility, chemotherapy selection, and radiotherapy planning.
Based on the TNM data, the AJCC groups patients into four stage categories. The table illustrates typical characteristics and recommended treatment modalities for each stage.
Radiologic findings are integrated with surgical and pathological data to refine staging. Multiphase contrast CT is used to assess vascular encasement, while MRI helps clarify borderline resectability. At Liv Hospital, a dedicated radiology team reviews all images in a multidisciplinary conference, ensuring consensus on the final stage.
For patients traveling from abroad, Liv Hospital provides a seamless diagnostic pathway that begins before arrival. A dedicated International Patient Coordinator arranges appointments, visa assistance, and airport transfers, allowing the medical team to focus on clinical evaluation.
The diagnostic MDT includes:
The table outlines each professional’s role during the diagnostic phase.
From first contact to a finalized stage report, most patients complete the process within 7‑10 days:
EUS remains the most sensitive modality for detecting small pancreatic lesions. Elastography, an add‑on that measures tissue stiffness, improves differentiation between malignant and benign masses, reducing unnecessary biopsies.
Next‑generation sequencing (NGS) of biopsy material identifies actionable mutations such as KRAS, BRCA1/2, and MSI‑high status. Liquid biopsy—analyzing circulating tumor DNA (ctDNA) from peripheral blood—offers a non‑invasive method to monitor disease dynamics and detect early recurrence.
Hybrid PET/MRI combines metabolic and high‑resolution anatomic data in a single session, providing unparalleled detail for staging borderline resectable disease. Early experience at Liv Hospital shows improved detection of small liver metastases compared with PET/CT alone.
The following comparison highlights the strengths of each emerging tool.
To ensure a smooth diagnostic experience, international patients should complete the following items before traveling:
Liv Hospital offers a range of concierge services tailored for diagnostic visits:
The table below summarizes the support package for a standard diagnostic stay (3‑5 days).
Liv Hospital combines JCI accreditation, a multilingual care team, and state‑of‑the‑art diagnostic facilities to deliver world‑class pancreatic cancer assessment. International patients benefit from a fully coordinated experience that includes travel logistics, interpreter services, and personalized medical planning—all under one roof.
Ready to start your diagnostic journey with confidence? Contact our International Patient Office today to schedule a virtual consultation and secure your personalized care plan at Liv Hospital.
Send us all your questions or requests, and our expert team will assist you.
Contrast‑enhanced CT is the first‑line tool for detecting the primary tumor and assessing vascular involvement. MRI with MRCP provides superior ductal anatomy detail, especially useful for borderline lesions. Endoscopic ultrasound (EUS) offers high‑resolution images and enables real‑time tissue acquisition via fine‑needle aspiration. PET/CT adds metabolic information to identify distant metastases. Together, these modalities give a comprehensive view of tumor size, location, and spread, guiding treatment decisions.
The American Joint Committee on Cancer (AJCC) TNM system grades pancreatic tumors from T0‑T4 based on size and local invasion, N0‑N2 for regional lymph node spread, and M0‑M1 for absence or presence of distant metastasis. Combining these values yields an overall stage I‑IV, which determines surgical eligibility, chemotherapy options, and prognosis. Accurate TNM staging requires high‑quality imaging and histologic confirmation.
At Liv Hospital, an MDT includes gastroenterologists (EUS‑FNA), radiologists (CT/MRI/PET interpretation), oncologic surgeons (resectability assessment), medical oncologists (systemic therapy planning), pathologists (histology and molecular profiling), nutritionists, and psychologists. Weekly conferences review all data, producing a consensus stage report within 7‑10 days. This collaborative approach reduces delays, improves diagnostic accuracy, and aligns treatment with each patient’s unique clinical profile.
EUS‑elastography measures tissue stiffness, helping differentiate malignant from benign lesions and reducing unnecessary biopsies. Next‑generation sequencing (NGS) of biopsy tissue identifies actionable mutations (e.g., KRAS, BRCA, MSI‑high) for targeted therapy. Liquid biopsy analyzes circulating tumor DNA, offering a non‑invasive method to monitor disease dynamics and detect recurrence earlier than imaging. Hybrid PET/MRI combines metabolic and high‑resolution anatomic data, enhancing detection of small liver metastases and borderline resectable disease.
Before traveling, patients should obtain copies of any prior imaging studies, list all medications and supplements, and follow fasting guidelines (typically 6 hours before CT or EUS). Securing travel insurance that covers oncologic procedures is essential. The International Patient Office will send an online health questionnaire to complete. Liv Hospital also provides airport pick‑up, hotel arrangements, interpreter services, and a dedicated liaison to coordinate appointments and answer clinical questions, ensuring a smooth diagnostic experience.
BlogCancerFeb 19, 2026Receiving a diagnosis of a pancreatic tumor can be a frightening experience, but understanding the type of ...
BlogCancerFeb 19, 2026Living with a tumor in the pancreas is tough. The quality of life and survival rates depend on the tumor ty...
BlogCancerFeb 19, 2026Pancreatic cancer is becoming a big problem worldwide. We see a worrying trend where new cases are projecte...
BlogCancerFeb 19, 2026Pancreatic cancer is a big health issue. Knowing when most people get it is key to catching it early. Most ...
BlogCancerFeb 19, 2026Finding pancreatic cancer early is hard because its symptoms are not clear. Also, blood tests can’t a...
BlogCancerFeb 19, 2026Pancreatic cancer is often called a silent killer because its early signs are subtle. These signs are often...
